Navigation Links
Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer

irs, Bristol-Myers Squibb. "We are anxious to understand these data in greater detail and are committed to exploring the potential benefits that ERBITUX may provide to cancer patients."

This year in the U.S., approximately 33,700 people will be diagnosed with cancer of the pancreas. Pancreatic cancer accounts for about six percent (6%) of all cancer deaths, or about 32,000 deaths per year. The current 5-year survival rate is about five percent (5%). The number of deaths from this disease highlights the importance of seeking better therapies for pancreatic cancer through clinical trials testing novel drugs. During the past 30 years, the numbers of new cases of pancreatic cancer (incidence) and deaths (mortality) have changed little.

ERBITUX is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells called the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1). In vitro assays and in vivo animal studies have shown that binding of ERBITUX to the EGFR blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production. In vitro, ERBITUX can mediate antibody-dependent cellular cytotoxicity (ADCC) against certain human tumor types. While the mechanism of ERBITUX' anti-tumor effect(s) in vivo is unknown, all of these processes may contribute to the overall therapeutic effect of ERBITUX. EGFR is part of a signaling pathway that is linked to the growth and development of many human cancers, including those of the head and neck, colon and rectum.

ERBITUX (Cetuximab), in combination with radiation therapy, is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck. ERBITUX as a single agent is indicated for the treatment of patients with recurrent or metastatic squ
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
3. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:12/17/2014)... , Dec. 17, 2014  Northstar Global Business ... Trust Company (DTC) has made their final decision ... on the Company,s stock effective December 15, 2014, ... stock for depository and book entry transfer services. All ... is now once again fully "DTC Eligible", and ...
(Date:12/17/2014)... Dec. 17, 2014  Beamz Interactive, Inc. (OTCQB: ... products, today announced that it has signed an ... and supplier of innovative prosthetic, orthotic and assistive ... of the agreement, RSL Steeper will promote and ... configured for use within UK residential care facilities ...
(Date:12/17/2014)... LOS ANGELES , Dec. 17, 2014 /PRNewswire/ ... that the US Patent and Trademark Office (USPTO) ... candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting ... glioblastoma. The claims of US Patent No. 8,871,211, ... treating neural cancer by administering a dendritic cell ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... SAN DIEGO, June 16, 2011 Neurocrine Biosciences, Inc. ... elagolix presentations have been accepted for the scientific program ... September 4-7, 2011 in Montpellier, France. This important meeting ... every three years, bringing together clinicians and basic scientists ...
... 2011 Cebix Incorporated announced today it ... for the treatment of complications of diabetes. The biopharmaceutical ... evaluate Ersatta™, its proprietary long-acting form of C-peptide, in ... disease, lack this endogenous peptide.  Following the successful completion ...
Cached Medicine Technology:Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis 2Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis 3Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 2Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 3Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 4
(Date:12/20/2014)... 2014 Recently, AngelWeddingDress.com has introduced its ... for the coming Christmas. In the promotion, all buyers ... , “We have something special for the women who ... season. Moreover, our new collections of 2015 dresses have ... now at greatly discounted prices. Visit our website now ...
(Date:12/20/2014)... The Twin Cities DI Day is ... the nation! Over 250 financial professionals come together each ... the industry, get motivated to protect their clients and ... and overcoming the challenges of disability. , On September ... came together to attend The 13th Annual Twin Cities ...
(Date:12/19/2014)... Today, Balfleet.com , a leading dress company ... dress promotion. All the old and new customers can ... Balfleet.com is well-known for its high quality trendy women’s ... dresses and more. Its formal dresses are quality made ... can create an elegant look when paired with any ...
(Date:12/19/2014)... 19, 2014 Sub Zero Ice Cream is ... blood drive Sunday the 28th from 2pm-6pm at the Expo ... Road in Sarasota, FL. , Inquiries regarding time slots and ... participating in the donating process, Sub Zero Ice Cream & ... custom ice cream. , About Sub Zero Ice Cream & ...
(Date:12/19/2014)... December 19, 2014 Silver Dollar City ... world record -- for the first time ever, Silver Dollar ... book, Guinness World Records 2015, listing the park’s wood coaster ... Coaster. In additional awards announced this week, Silver Dollar City ... Lights in the US,” USA Today’s 10Best awards for “Best ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2
... Singapore – The accomplishments of Thailand and Cambodia in ... been achieved primarily through the extensive use of condoms.// ... at Singapore's Ministry of Health, said "The 100 per ... two prominent examples of successful prevention efforts." ...
... have long been the cornerstones of managing type 2 ... these patients.// ,Now, a new systematic review shows ... the body’s sensitivity to insulin, and decreases blood lipids ... ,“Type 2 diabetes is an increasing problem in ...
... lay claim to the 'bird flu free nation' status next month, ... country for the last three months, federal Agriculture Minister Sharad Pawar ... avian influenza for the last three months, which makes us eligible ... ,The claim would be made before the World Organisation for ...
... a four-year project at 25 health care institutions around ... & Prevention// (CDC), implemented findings from successful clinical trials ... families. ,The purpose of the ICAI project ... & Immunology, the scientific journal of the American College ...
... the department of gynecology at the Catholic University of ... on the disease// endometriosis to identify its cause and ... results in the growth of the endometrial tissue outside ... are bleeding, pain, inflammation, adhesions and infertility. Statistics show ...
... in Malaysia have been forbidden to use Botox injections, for ... ,The National Fatwa Council issued the ban yesterday ... conditions such as cerebral palsy on the condition that it ... necessary for patients who do not have any other alternative., ...
Cached Medicine News:Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 2Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 3Health News:Groundbreaking Asthma Intervention Lessons Help Inner-City Children 2
Karlin Lumbar Microdiscectomy Curette, length 9 1/2" (24.13 cm)....
PG Magnum Cup Curettes with large capacity cup sizes, total length 12.6" (32 cm) handle length 7.8" (20 cm), handle diameter 1.12" (3 cm), working distance 4.7" (12 cm)....
Karlin Cervical Microdiscectomy Curette, length 8 1/2" (21 cm)....
Microsect Curette with increased cutting edge and modified shaft, 10"....
Medicine Products: